NMI 870
Latest Information Update: 18 Mar 2008
At a glance
- Originator NitroMed
- Class
- Mechanism of Action Alpha 2 adrenergic receptor antagonists; Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Erectile dysfunction; Female sexual dysfunction
Most Recent Events
- 06 Mar 2008 NitroMed's nitric oxide-enhancing technologies are available for licensing
- 06 Mar 2008 Discontinued - Phase-II for Erectile dysfunction in USA (unspecified route)
- 06 Mar 2008 Discontinued - Phase-II for Female sexual dysfunction in USA (unspecified route)